Vol.2 No.3

Stem Cell Research 2017 : Nano-diamino-tetrac (NDAT; Nanotetrac) acts at its target on integrin $\tilde{A}\check{Z}\hat{A}\pm v\tilde{A}\check{Z}\hat{A}^{2}$ 3 in human glioblastoma xenografts to induce necrosis via. anti-angiogenesis and apoptosis_ Paul J Davis_ Albany College of Pharmacy and Health Sciences, USA

Paul J Davis

Albany College of Pharmacy and Health Sciences, USA

Clinical evidence in a limited number of patients supports the concept that glioblastoma multiforme (GBM) is a thyroid hormone-dependent cancer. In vitro evidence indicates that Lthyroxine (T4), the principal secretory product of the thyroid gland, at physiological concentrations stimulates proliferation of glioma /GBM cancer cells via a poly-functional cell surface receptor for T4 on the extracellular domain of cancer cell plasma membrane integrin $\alpha v\beta 3$. This action of T4 is blocked by nanoparticulate tetraiodothyroacetic acid (Nanotetrac, Nanodiamino-tetrac, NDAT). Tetrac in this NDAT formulation is covalently bound via a diaminopropane linker to a poly(lacticco-glycolic acid) (PLGA) nanoparticle. We have examined histopathologically the induction bv NDAT of devascularization, of necrosis and apoptosis in U87MG human GBM cell xenografts in nude mice. Treatment regimen was 1 mg tetrac equivalent/kg body weight s.c. as NDAT daily X10 d, begun 2 d following tumor cell implantation when tumor volume estimates were 350 mm3. Xenografted control animals received void nanoparticulate PLGA. Xenograft weight in treated animals at sacrifice was reduced by 50% (P<0.01). Tumor area measured in histologic sections was reduced by 80% in treated animals compared to controls (P<0.001). Blinded analysis of changes in histologic slides from xenografts revealed essentially complete loss of tumor blood vessels with NDAT (P<0.001 vs. control xenografts). This finding was associated with no evidence of hemorrhage. Eighty percent of the cell population in grafts was either necrotic or apoptotic (P<0.001 vs. control) and cell density was reduced by 60% vs. control tumors (P <0.001 vs. control). Mitotic figures/field examined was reduced by 80%. In summary, NDAT, acting at the thyroid hormone- tetrac receptor on the extracellular domain of integrin α v β 3, devascularized human GBM xenografts with resultant widespread necrosis. In the tumor cell population that was not necrotic, drug-induced apoptosis was documented. The thyroid hormone receptor on $\alpha v\beta 3$ in U87MG cells is a single endocrine target with multiple downstream functions that are exploited by anticancer and antiangiogenic actions of NDAT (P<0.001 vs. control). Nano-diamino-tetrac (NDAT; Nano-tetrac) is an anticancer/anti-angiogenic agent targeted to the thyroid hormone-tetrac receptor on the extracellular domain of integrin α v β 3. He has good experience in the field of Cancer cell and stem cells and cell Biology. He is former Chair at the Department of Medicine, Albany Medical

College. He is also an Endocrine Researcher. He described about thyroid hormone-tetrac receptor on integrin $\alpha v\beta 3$.

NDAT inhibits PD-L1 inducible expression and protein accumulation by inhibition of activated ERK1/2 and PI3K. Knockdown PD-L1 has also inhibited the proliferation of oral cancer cells which suggests that the inhibitory effect of NDAT on the expression PD-L1 is perhaps one of the critical mechanisms for the NDAT-induced anti-proliferation effect in oral cancer cells. The graft shrinkage per day 10 in treated animals was at least 50% in weight/volume and 80% in the area on histological slides, compared to controls.

Its nano-particulate analogue, nano-diamino-tetrac (NDAT; Nanotetrac) is an anti-cancer/anti-angiogenic agent. In this study, the inhibitory mechanism by which NDAT inhibited the abundance of PD-L1 RNAM and the content of PD-L1 proteins in oral cancer cells was studied

This abstract is partly presented at the Joint Event on 8th World Congress and Expo on Cell & Stem Cell Research March 20-22, 2017 Orlando, Florida, USA